# EvolutionaryScale

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/evolutionaryscale

- Industry: Software
- Headquarters: San Francisco, US
- Website: www.evolutionaryscale.ai/
- Total disclosed funding: $142M
- Latest round: Seed (Jun 25, 2024)
- Investors on record: 3

## About

Founded in 2023 by Alexander Rives, Tom Sercu, and Thomas Hayes and based in California, US, EvolutionaryScale offers generative artificial intelligence models to generate novel proteins for material science and drug discovery applications. In June 2024, EvolutionaryScale raised USD 142 million in seed funding co-led by investor Lux Capital and individual investors, with participation from other investors NVentures and Amazon.

ESM3 offers a generative AI model that is trained on a massive dataset of protein sequences and can be used for various purposes, such as understanding existing proteins, designing new ones with specific properties, and even predicting protein structures. Additionally, EvolutionaryScale offers ESM3 in three sizes: small, medium, and large. These are accessible through their API and partner platforms, with a free open-source version available for non-commercial research. It leverages the computational power of over 1x10^24 FLOPS and 98 billion parameters, trained on a diverse dataset spanning billions of proteins from various ecosystems worldwide. The company's products cater to a diverse range of applications, from designing novel fluorescent proteins like esmGFP to envisioning enzymes for environmental remediation and pioneering new medicines.

The company will use the June 2024 funding to further develop its generative AI model to integrate data beyond proteins and create general-purpose AI models for biotech applications.

## Funding rounds

- Seed, Jun 25, 2024, $142M — Lux Capital, Amazon, NVentures

## Investors

- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Seed
- Amazon (https://capitalatlas.ai/funds/amazon) — Seed
- NVentures — Seed